|08/29/14||Thoratec Presentation At Morgan Stanley Healthcare Conference To Be Webcast|
|PLEASANTON, Calif., Aug. 29, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September 10.
Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 12:55 p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Ti... |
|08/06/14||Thoratec® Reports Second Quarter 2014 Results|
|- Revenue of $118.1 million for the second quarter of 2014
- GAAP Net Income per Diluted Share of $0.30, and Non-GAAP Net Income per Diluted Share of $0.43
- Company adjusts full-year 2014 guidance for revenue to a range of $455 million to $470 million and for net income per diluted share to $0.80 to $0.90 on a GAAP basis and $1.25 to $1.35 on a non-GAAP basis
- HeartMate III™ and HeartMate PHP™ begin CE Mark Trials; FDA grants conditional approval to start HeartMate III U.S. IDE trial
|08/06/14||Thoratec Announces $30 Million Accelerated Share Repurchase|
|PLEASANTON, Calif., Aug. 6, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has entered into a $30 million Accelerated Share Repurchase (ASR) agreement.
"This commitment to capital deployment reflects our ongoing conviction in the long term opportunities in our business," said Gary F. Burbach, President and Chief Executive Officer. "Furthermore, o... |